Semaglutide
Semaglutide in kidneys, hearts and eyes
FLOW begins with kidneys already affected by disease. That makes it a particularly useful place to consider what treatment can preserve.
FLOW kidney trial
The people in FLOW had type 2 diabetes and chronic kidney disease. Among 3,533 participants, semaglutide reduced a combined outcome of major kidney events and deaths. The count included kidney failure, a loss of at least 50% of filtering ability from baseline, and death from kidney or cardiovascular causes. A participant needed to experience one of those events to enter the count.
The precision of FLOW’s question impresses me. Filtering blood is a particular job; the trial asked whether people with existing disease experienced fewer serious events. The result has a population and a concrete purpose. Its relevance depends on those circumstances.
Semaglutide copies GLP-1, a hormone released around meals. It helps the pancreas release insulin when glucose rises, suppresses inappropriate glucagon release and slows stomach emptying. Its engineered resistance to breakdown and reversible attachment to a blood protein help it remain active longer than natural GLP-1. The safety review discusses its pharmacology and clinical effects.
Cardiovascular outcomes; retinopathy
SELECT enrolled 17,604 adults with overweight or obesity and established cardiovascular disease, without diabetes. Semaglutide reduced the combined outcome of cardiovascular death, nonfatal heart attack or nonfatal stroke. Only the first qualifying event for each participant entered that primary count.
SUSTAIN-6 studied 3,297 people with type 2 diabetes at high cardiovascular risk. It also found fewer major cardiovascular events, alongside more complications of diabetic retinopathy, damage to the light-sensitive tissue at the back of the eye. Existing eye disease and rapid improvement in glucose control are important to the interpretation. The safety review discusses early worsening with rapid glucose correction as a possible explanation.
I feel less comfortable with a sweeping description such as “protective” after putting these findings together. The heart result is substantial. The eye result asks for attention to the condition of another organ and to how quickly circumstances change. Both came from the same treatment story.
Semaglutide weight trials
In rodent experiments, semaglutide reached several appetite-related brain regions and reduced food intake while changing food preference, without decreasing energy expenditure. Those experiments help explain an appetite effect in mice and rats. Human weight trials answer the treatment question directly.
STEP 1 enrolled adults with overweight or obesity without diabetes. At 68 weeks, mean body-weight change was −14.9% with semaglutide and −2.4% with placebo. In the direct SURMOUNT-5 comparison over 72 weeks, the means were −20.2% with tirzepatide and −13.7% with semaglutide. Those are weight findings from their respective trials.
I admire the larger weight reduction in that direct comparison; FLOW earns a separate place through the particular difficulty it addresses. Its question concerns serious events in people with kidney disease. A weight comparison leaves that question to a study designed to answer it.
Digestive tolerability
The semaglutide safety review describes predominantly mild-to-moderate, transient digestive adverse effects and an increased risk of biliary disease, including gallstones. Pancreatic- and thyroid-cancer signals remained unresolved because cases were uncommon. Pancreatitis also remains a warning. Weight loss can include lean tissue, and weight can return after treatment stops.
Community accounts describe quieter thoughts about food, altered tastes, nausea, constipation and unpleasant burping. These are anecdotal accounts, not clinical evidence; neither their frequency nor their cause can be established from the accounts. Those descriptions of discomfort deserve attention, while leaving causation open.
Semaglutide has FDA-approved prescription uses, including type 2 diabetes and weight management; particular products also have approvals concerning illness risk. The approved product and its label determine the indication. Compounded preparations and research chemicals do not acquire that approval by sharing the ingredient’s name. Personal treatment decisions require a clinician who can consider the person, the preparation and the other medicines involved.